Nasdaq:MRKR
Marker Therapeutics, Inc.
A clinical-stage biopharma firm developing proprietary antibody-drug conjugates for solid tumor and inflammatory disease indications with significant cash reserves.
Key Metrics
Investment Thesis
Bull Case
Investors may consider this stock for exposure to a differentiated ADC platform with potential high-value indications in oncology where current treatments show limited efficacy. The company maintains a robust cash position relative to its annual burn rate, providing runway to advance key assets without immediate equity dilution, and has recently demonstrated revenue stabilization after a period of decline.
Bear Case
The stock carries substantial risk due to consistent multi-million dollar losses over the past three years with no commercial products on the market yet. Revenue volatility from $9M in 2022 down to $3.3M in 2023 suggests an unstable top line, and the massive negative retained earnings deficit indicates a heavy reliance on external capital markets which may dry up if clinical milestones are not met.
About Marker Therapeutics, Inc.
Marker Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory diseases and cancer indications. The company primarily serves the global oncology and rare disease markets with its proprietary antibody-drug conjugate platform targeting solid tumors. Key products are currently in preclinical or early clinical development stages, leveraging a unique technology platform to advance pipeline candidates through regulatory review.
Analysis
Management Discussion
Despite a slight revenue recovery to $6.6M in 2024 compared to 2023, the company continues to report significant operating losses of $-10.7M driven by substantial R&D expenditures of $13.5M and general administrative costs of $4.2M. The net change in cash remains positive at $4.1M due to strong financing inflows, yet the cumulative retained earnings deficit stands at -$447M, highlighting the capital-intensive nature of early-stage biotech development.
Industry Overview
The biotechnology sector is highly competitive with rapid technological advancements in antibody-drug conjugates and precision medicine driving innovation but also increasing development costs. Success in this industry hinges on the ability to advance preclinical candidates through costly Phase I/II trials while managing cash flow constraints until regulatory approval is secured for commercialization.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $9.0M | $3.3M | $6.6M |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $9.0M | $3.3M | $6.6M |
| Operating Expenses | $39.0M | $17.9M | $17.7M |
| Operating Income | $-29.9M | $-14.6M | $-11.1M |
| R&D | $26.1M | $10.4M | $13.5M |
| G&A | $12.8M | $7.5M | $4.2M |
| Stock-Based Comp | $5.3M | $858.3K | $245.9K |
| D&A | $2.8M | — | — |
| Depreciation | $2.8M | — | — |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $0 | $539.2K | $437.0K |
| Interest Income | $248.1K | $539.2K | $437.0K |
| Pre-Tax Income | $-29.9M | $-14.0M | $-10.7M |
| Income Tax | $-15.1K | $3.7K | $50.0K |
| Continuing Ops | $-29.9M | $-14.0M | $-10.7M |
| Discontinued Ops | $0 | $5.8M | $0 |
| Net Income | $-29.9M | $-8.2M | $-10.7M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-29.9M | $-8.2M | $-10.7M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $16.6M | $17.1M | $22.0M |
| Cash & Equivalents | $11.8M | $15.1M | $19.2M |
| Other Current Assets | $4.8M | $2.0M | $2.8M |
| Long-Term Assets | $17.8M | $0 | $0 |
| PP&E (Net) | $12.3M | — | — |
| Operating Leases | $5.5M | — | — |
| Other LT Assets | $143 | — | — |
| Total Assets | $34.4M | $17.1M | $22.0M |
| Current Liabilities | $7.8M | $3.1M | $3.5M |
| Accounts Payable | $1.6M | $961.0K | $1.1M |
| Current Leases | $577.2K | — | — |
| Other Current Liab | $5.6M | $2.1M | $2.4M |
| Long-Term Liabilities | $7.0M | $0 | $0 |
| LT Operating Leases | $7.0M | — | — |
| Other LT Liab | $0 | — | — |
| Total Liabilities | $14.8M | $3.1M | $3.5M |
| Shareholders' Equity | $19.6M | $14.1M | $18.6M |
| Paid-In Capital | $447.6M | $450.3M | $465.6M |
| Retained Earnings | $-428.0M | $-436.3M | $-447.0M |
| Total L&E | $34.4M | $17.1M | $22.0M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-29.9M | $-8.2M | $-10.7M |
| Non-Cash Adjustments | $4.1M | $-6.6M | $-1.4M |
| Working Capital Changes | $-1.1M | $-1.6M | $1.2M |
| Cash from Operations | $-27.0M | $-16.4M | $-10.9M |
| Cash from Investing | $-4.9M | $18.7M | $0 |
| Cash from Financing | $202.1K | $1.1M | $15.0M |
| FX Effect | $43.5M | $0 | $0 |
| Net Change in Cash | $11.8M | $3.3M | $4.1M |
| Beginning Cash | $43.5M | $11.8M | $15.1M |
| Ending Cash | $11.8M | $15.1M | $19.2M |
Frequently Asked Questions
How does Marker Therapeutics, Inc. make money?
Oncology Development (primary focus on antibody-drug conjugates), Inflammatory Disease Research, and Technology Licensing.
What are the main risks for MRKR?
Clinical trial failure risks for preclinical assets, limited revenue diversification relying entirely on future product approvals, ongoing net losses exceeding $10M annually impacting retained earnings, and high dependence on successful fundraising to sustain operations given current cash burn rates.
What is MRKR's competitive advantage?
Proprietary antibody-drug conjugate platform targeting difficult-to-treat solid tumors, strong balance sheet with over $19M in cash and equivalents to fund R&D without immediate dilution, and a lean operational structure with minimal long-term liabilities.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.